Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

  title={Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain},
  author={Michael Iskedjian and Basil G Bereza and Allan S. Gordon and Charles Piwko and Thomas R Einarson},
  journal={Current Medical Research and Opinion},
  pages={17 - 24}
ABSTRACT Objective: Debilitating pain, occurring in 50–70% of multiple sclerosis (MS) patients, is poorly understood and infrequently studied. We summarized efficacy and safety data of cannabinoid-based drugs for neuropathic pain. Data sources: Studies were identified from Medline, Embase, and Cochrane databases; Bayer Healthcare provided additional trials. Study selection: Accepted were randomized, double-blinded placebo-controlled trials of cannabinoid-based treatments for MS-related… 

Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis

Well-designed, large, randomized studies are required to better evaluate specific dosage, duration of intervention, and the effect of this intervention on physical and psychologic function in patients with chronic NP.

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome.

Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

A systematic review and meta-analysis of all randomized controlled trials of Cannabis-based medicines suggests that CBMs might be effective for chronic pain treatment, based on limited evidence, primarily for neuropathic pain patients.

Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression

Efficacy for neuropathic and non-neuropathic pain was similar, and pain intensity of chronic non-cancer patients was reduced by cannabinoids consumption, but effect sizes were small.

Systematic review and meta-analysis of cannabis treatment for chronic pain.

Systematic review and meta-analysis of double-blind randomized controlled trials that compared any cannabis preparation to placebo among subjects with chronic pain suggests that cannabis treatment is moderately efficacious for treatment of chronic pain, but beneficial effects may be partially (or completely) offset by potentially serious harms.

The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review.

Cannabis-based medicinal extracts used in different populations of chronic nonmalignant neuropathic pain patients may provide effective analgesia in conditions that are refractory to other treatments.

Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data.

Nabiximols in chronic neuropathic pain: a meta-analysis of randomized placebo-controlled trials.

Nabiximols was superior to placebo for reduction of chronic neuropathic pain, with a small effect size, in larger RCTs designed to assess the effect of nabiximol in neuropathicPain.

Tetrahydrocannabinol in the treatment of neuropsychiatric symptoms in dementia

Two studies showed that THC might be useful in treatment of anorexia and behavioral symptoms in dementia, and adverse events were more common during cannabinoid treatment compared to the control treatment, and were most frequently sedation like symptoms.



Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

Dronabinol has a modest but clinically relevantanalgesic effect on central pain in patients with multiple sclerosis and on the SF-36 quality of life scale, the two items bodily pain and mental health indicated benefits from active treatment compared with placebo.

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

CBM was generally well tolerated, although more patients on CBM than placebo reported dizziness, dry mouth, and somnolence, and Cognitive side effects were limited to long-term memory storage.

Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.

In this preliminary study, CT-3 was effective in reducing chronic neuropathic pain compared with placebo and no major adverse effects were observed.

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

Spasticity VAS scores were significantly reduced by CBME (Sativex) in comparison with placebo (P- 0.001), there were no significant adverse effects on cognition or mood and intoxication was generally mild.

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

Cannabis medicinal extracts can improve neurogenic symptoms unresponsive to standard treatments, and unwanted effects are predictable and generally well tolerated.

Delta‐9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief

The unaffected electrically induced axon reflex flare, but decreased pain perception, suggests a central mode of action of the cannabinoid, and demonstrates that a generalized statement that delta‐9-THC is an analgetic drug cannot be made.

Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 ‘N of 1’ studies

A total of 34 ‘N of 1’ studies were undertaken using this novel therapy for patients with chronic, mainly neuropathic, pain and associated symptoms to explore efficacy, tolerability, safety and dosages of CBME.

Cannabinoid Analgesia as a Potential New Therapeutic Option in the Treatment of Chronic Pain

Cannabinoids provide a potential approach to pain management with a novel therapeutic target and mechanism, and cannabinoids are a potential addition to the arsenal of treatment options.